Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Nephrology
•
Endocrinology
•
Electrolyte disorders
•
Bone and Calcium Disorders
Do you routinely check N-telopeptide levels in patients who you suspect might have immobilization induced hypercalcemia?
Related Questions
What is your approach to IV fluid management for the treatment of hypercalcemia of malignancy?
Is there a role for cinacalcet in the management of PTHrP-mediated hypercalcemia?
What is the recommended workup for PTH-independent hypercalcemia secondary to an elevated 1,25-dihydroxyvitamin D level?
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
How do you approach vitamin D supplementation in patients with chronic kidney disease, given the findings that vitamin D2 supplementation may lead to decreased conversion of 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3?
Do you prefer kidney ultrasound or a non-contrast CT scan to evaluate for nephrolithiasis in an asymptomatic patient with primary hyperparathyroidism?
Should we aim to reduce or stop thiazides in patients with thiazide-induced hypercalcemia given its similar risk profile to untreated primary hyperparathyroidism?
What is your approach to treating immobilization hypercalcemia?
Would you use a parathyroid hormone analog for treatment of osteoporosis in a patient with mildly elevated AlkPhos of unclear etiology?
Do patients with 25 OH vitamin D levels under 20 ng/ml and normal PTH levels ("relative hypoparathyroidism") still carry a risk for bone and calcium metabolism disorders such as osteomalacia?
